
Dr. Falk Pharma’s PSC drug achieves endpoints in Phase III trial
Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing cholangitis (PSC). In the pivotal, Phase III NUC-5 trial, (NCT03872921), NCA showed statistical superiority over placebo in achieving the …